| Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. | |
| | |
MedLine Citation:
|
PMID: 21845032 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex(®), a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United States in 2009. Since then, new therapeutic agents and clinical data have emerged. The purpose of this review is to critically evaluate the clinical utility of Ozurdex(®) in the current treatment strategy of macular edema related to retinal vein occlusion. |
| | |
Authors:
|
Annie Chan; Loh-Shan Leung; Mark S Blumenkranz |
Publication Detail:
|
Type: Journal Article Date: 2011-07-26 |
Journal Detail:
|
Title: Clinical ophthalmology (Auckland, N.Z.) Volume: 5 ISSN: 1177-5483 ISO Abbreviation: Clin Ophthalmol Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-08-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101321512 Medline TA: Clin Ophthalmol Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1043-9 Citation Subset: - |
Affiliation:
|
Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Changes in corneal parameters at confocal microscopy in treated glaucoma patients.
Next Document: Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choro...